Drug · Gene Therapy

Letetresgene Autoleucel

CI-DRUG-00000338Explore in graph →NCIt C121379 CHEMBL4650238 CIViC Phase 2

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	1	0	0	7	0	—	—	Feb 1, 2016

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 17 hours agoSource updated unknown

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CTAG1B Overexpression1
Letetresgene Autoleucel

Clinical trials

Trials with this intervention (7)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–7 of 7 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05993299	Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma	completed	Phase 2	7	USWM, LLC (dba US WorldMeds)INDUSTRY	7	Sep 2, 2026	clinicaltrials
NCT06703346	Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Molecule

Record

Kind: Gene Therapy
Aliases: Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794, Autologous T-Cells Expressing Enhanced TCRs Specific For NY-ESO-1/LAGE-1a GSK3377794, Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794, Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794, GSK-3377794, GSK3377794, Letetresgene Autoleucel, NY-ESO-1c259 T Cells GSK3377794

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.